• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

byBoaz WongandHarsh Shah
May 9, 2022
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant nivolumab in addition to platinum-based chemotherapy demonstrated longer survival and treatment response after resection compared to patients only receiving chemotherapy.

2. Nivolumab treatment was not associated with any additional adverse events and did not impact the feasibility of surgical resection.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nivolumab is an anti-programmed death 1 (PD-1) antibody aimed to restore anti-tumor immune responses. In patients with resectable early-stage non-small cell lung cancer (NSCLC), neoadjuvant treatment with Nivolumab prior to surgery showed promise in improving complete responses to treatment and survival outcomes. In this phase 3 clinical trial named CheckMate 816, the primary objective was to evaluate improvements in event-free survival and pathological complete response in patients with resectable NSCLC by neoadjuvant nivolumab. Selected patients were randomized in a 1:1 ratio to either receive three cycles of nivolumab plus platinum-based chemotherapy, or chemotherapy alone prior to surgical resection. The results of this study found that patients receiving nivolumab demonstrated significantly increased event-free survival and proportion of pathological complete response. Other secondary measures of overall survival, time to death or metastases, and radiographic downstaging also favored the group receiving nivolumab. More patients in receiving nivolumab successfully underwent surgical resection. Incidence rates of severe adverse events were similar between both groups. Taken together, this study supports the neoadjuvant use of nivolumab in patients with resectable NSCLC to improve survival and response to treatment. As a result, neoadjuvant nivolumab plus chemotherapy has been approved for clinical use in the United States in this patient population.

Click to read the study in NEJM 

Relevant Reading: Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

RELATED REPORTS

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

In-Depth [randomized controlled trial]: In this phase 3, open-label, international, multicenter randomized control trial named CheckMate 816, 358 patients with early-stage (IB – IIIA) non-small cell lung cancer (NSCLC) eligible for surgical resection were randomized in a 1:1 ratio to receive either 360 mg nivolumab and platinum-doublet chemotherapy, or chemotherapy alone for 3 cycles for completion 6 weeks prior to planned surgery. Patients were followed for the primary outcome of event-free survival, which was the time from randomization to any progression of disease or death, which was statistically compared using the stratified log-rank test. The other primary endpoint was pathological complete response, which described no viable residual tumor cells from primary tumor biopsy samples or associated lymph nodes, statistically compared using a Cochran-Mantel-Haenszel test. Secondary endpoints assessed any major pathological response, time to death or distant metastases, and overall survival. Across the cohort, 83.2% of patients receiving nivolumab-plus-chemotherapy underwent surgery, compared to 75.4% in the chemotherapy-only group. Patients receiving nivolumab had a significantly shorter median event-free survival of 31.6 months compared to 20.8 months in their chemotherapy counterparts (hazard ratio [HR], 0.63; 97.38% confidence interval [CI], 0.43-0.91; P=0.005). The nivolumab-plus-chemotherapy group also had a significantly greater proportion of patients who complete pathological response at 24% vs. 2.2% (odds ratio [OR], 13.94, 99% CI, 3.49 – 55.75; P<0.001). These trends held true for other subgroup analyses. However, no significant differences in overall survival were observed between groups in the first interim analysis which may require a longer follow-up period. Finally, the incidence of severe adverse events (grade 3 or 4) was statistically similar between both groups. Overall, this study provides evidence to support the use of neoadjuvant nivolumab in addition to platinum-doublet chemotherapy in patients with resectable NSCLC to improve downstream outcomes of event-free survival and complete pathological response.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chemotherapyneoadjuvantneoadjuvant chemotherapyneoadjuvant nivolumabNivolumabnon-small cell lung cancer (NSCLC)
Previous Post

Single-incision mini-slings effective for urinary incontinence in women

Next Post

Treatment with chemoradiotherapy before systemic chemotherapy for rectal adenocarcinoma is a potential non-surgical option

RelatedReports

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 19, 2025
Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025
Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
Next Post
Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival

Treatment with chemoradiotherapy before systemic chemotherapy for rectal adenocarcinoma is a potential non-surgical option

Blindness and visual impairment decreasing worldwide

Preterm birth associated with differences in optic disc morphology in adulthood

Increased number of daily steps linked with decreased mortality in older women

An implantable system overcomes orthostatic hypotension in a patient with multiple-system atrophy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.